Tags

Type your tag names separated by a space and hit enter

[Pitavastatin and new diabetes development].
Turk Kardiyol Dern Ars. 2017 Apr; 45(Suppl 3):13-15.TK

Abstract

Managing dyslipidaemia is central to the management of cardiovascular disease. Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus. However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. Pitavastatin is a new member of the statin class. And pitavastatin has a number of pleiotropic effects that can reduce inflammation and lipid oxidation, improve endothelial function, reduce the metabolic changes associated with adiposity, and improve glucose metabolism and renal function.

Authors+Show Affiliations

No affiliation info availableDepartment of Endocrinology and Metabolic Diseases, Florence Nightingale Hospital, İstanbul, Turkey. kubilayukinc@me.com.

Pub Type(s)

Journal Article

Language

tur

PubMed ID

28952473

Citation

Beyaz, Şengül, and Kubilay Ükinç. "[Pitavastatin and New Diabetes Development]." Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir, vol. 45, no. Suppl 3, 2017, pp. 13-15.
Beyaz Ş, Ükinç K. [Pitavastatin and new diabetes development]. Turk Kardiyol Dern Ars. 2017;45(Suppl 3):13-15.
Beyaz, Ş., & Ükinç, K. (2017). [Pitavastatin and new diabetes development]. Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir, 45(Suppl 3), 13-15. https://doi.org/10.5543/tkda.2017.51635
Beyaz Ş, Ükinç K. [Pitavastatin and New Diabetes Development]. Turk Kardiyol Dern Ars. 2017;45(Suppl 3):13-15. PubMed PMID: 28952473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pitavastatin and new diabetes development]. AU - Beyaz,Şengül, AU - Ükinç,Kubilay, PY - 2017/9/28/entrez PY - 2017/9/28/pubmed PY - 2018/7/3/medline SP - 13 EP - 15 JF - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir JO - Turk Kardiyol Dern Ars VL - 45 IS - Suppl 3 N2 - Managing dyslipidaemia is central to the management of cardiovascular disease. Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus. However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. Pitavastatin is a new member of the statin class. And pitavastatin has a number of pleiotropic effects that can reduce inflammation and lipid oxidation, improve endothelial function, reduce the metabolic changes associated with adiposity, and improve glucose metabolism and renal function. SN - 1308-4488 UR - https://www.unboundmedicine.com/medline/citation/28952473/[Pitavastatin_and_new_diabetes_development]_ L2 - https://www.journalagent.com/pubmed/linkout.asp?ISSN=1016-5169&PMID=28952473 DB - PRIME DP - Unbound Medicine ER -